Insulet Corp
NASDAQ:PODD

Watchlist Manager
Insulet Corp Logo
Insulet Corp
NASDAQ:PODD
Watchlist
Price: 263.23 USD -0.04%
Market Cap: 18.5B USD
Have any thoughts about
Insulet Corp?
Write Note

Insulet Corp
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Insulet Corp
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Insulet Corp
NASDAQ:PODD
Revenue
$2B
CAGR 3-Years
24%
CAGR 5-Years
23%
CAGR 10-Years
21%
Becton Dickinson and Co
NYSE:BDX
Revenue
$20.2B
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
9%
Boston Scientific Corp
NYSE:BSX
Revenue
$15.9B
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
8%
Stryker Corp
NYSE:SYK
Revenue
$22B
CAGR 3-Years
10%
CAGR 5-Years
9%
CAGR 10-Years
9%
Abbott Laboratories
NYSE:ABT
Revenue
$41.2B
CAGR 3-Years
-1%
CAGR 5-Years
6%
CAGR 10-Years
8%
Intuitive Surgical Inc
NASDAQ:ISRG
Revenue
$7.9B
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
14%
No Stocks Found

Insulet Corp
Revenue Breakdown

Breakdown by Geography
Insulet Corp

Total Revenue: 1.7B USD
100%
United States: 1.3B USD
75.8%
International: 410.1m USD
24.2%

Breakdown by Segments
Insulet Corp

Total Revenue: 1.7B USD
100%
Total Omnipod Products: 1.7B USD
97.9%
Drug Delivery: 36m USD
2.1%

Insulet Corp
Glance View

Market Cap
18.5B USD
Industry
Health Care
Economic Moat
Narrow

Insulet Corporation has carved out a significant niche in the medical device industry, distinguishing itself through its innovative approach to diabetes management. The company is best known for its Omnipod Insulin Management System, a discreet, tubeless insulin pump that provides a solution for individuals with diabetes seeking an alternative to traditional insulin delivery methods. Unlike conventional pumps that require cumbersome tubes and significant patient involvement, the Omnipod system offers ease and convenience, allowing users more freedom and flexibility in their daily lives. The system operates via a small wearable pod that delivers insulin over several days, which users control remotely, removing much of the hassle associated with managing diabetes. Insulet generates revenue by selling these pods and the associated Personal Diabetes Manager (PDM) devices, which together comprise the entire system. Customers typically purchase pods on a recurring basis, similar to a subscription model, which creates a steady stream of revenue for the company. The business model emphasizes continuous growth by expanding its user base and improving its technology to remain at the forefront of patient-centric diabetes care. Insulet's strategic focus on the needs of its users and commitment to refining their health technology has enabled it to build a sustainable business that addresses a critical healthcare challenge while also delivering consistent financial performance.

PODD Intrinsic Value
98.7 USD
Overvaluation 63%
Intrinsic Value
Price

See Also

What is Insulet Corp's Revenue?
Revenue
2B USD

Based on the financial report for Sep 30, 2024, Insulet Corp's Revenue amounts to 2B USD.

What is Insulet Corp's Revenue growth rate?
Revenue CAGR 10Y
21%

Over the last year, the Revenue growth was 27%. The average annual Revenue growth rates for Insulet Corp have been 24% over the past three years , 23% over the past five years , and 21% over the past ten years .

Back to Top